Abstract
The omega‐3 fatty acid docosahexanoic acid (DHA) is deposited in the brain early in life and plays an important role in neural and visual function. Little is known however about the benefits of ingesting DHA supplements during pregnancy for infant development. We conducted a randomized double‐blind placebo‐controlled trial of 400 mg/day algal DHA (Martek) from week 20 of gestation through delivery (n=1094 pregnant women) and followed the offspring (n=973 live births). Child development was measured in 730 children (75% of birth cohort) using the Spanish version of the Bayley Scales of Infant Development (BSID)‐II at 18 mo of age; we calculated standardized psychomotor development (PDI) and mental development indices (MDI). PDI and MDI scores (mean ± S.D.) were 94.3 ± 10.7 and 93.0 ± 8.9 in the DHA group (n=365) and 95.2 ± 9.3 and 93.3 ± 9.8 in the placebo group (n=365), respectively. Intent to treat differences in PDI and MDI scores at 18 mo were 0.90 (95% CI: −0.55, 2.35; p=0.23) and 0.26 (95% CI: −1.10, 1.63; p=0.70), respectively. Prenatal supplementation with 400 mg algal DHA did not result in improved global development scores at 18 mo of age in a study population (Mexico) with low intakes of DHA. Follow‐up of the cohort is ongoing. Funding: NIH (HD043099) and March of Dimes Foundation.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
